ERBB2 and breast cancer: In a recent immunohistochemical study of invasive female breast carcinoma, higher perlecan (HSPG2) expression was positively correlated with aggressive features (higher grade of tumour, advanced T stage and lymphovascular invasion, and high Ki-67 index and HER2 positivity), thereby confirming its use as a marker of BC progression [112].